According to WHO's report, more than 1 billion populations worldwide suffer from central nervous system (CNS) diseases including Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease and stroke. Despite enormous efforts, there is still no effective therapy for CNS diseases. One of major obstacles is whether or not a new drug can cross the blood-brain barrier to reach the designed target within the CNS. This requires the collection of cerebrospinal fluid (CSF) to assess the pharmacokinetics of the test drug within the CNS. However, this procedure is very difficult in animals because CSF can only be obtained from cannulation to the spinal cord under anesthesia.  

KBI has recently established the technique for accurate and continuous collection of CSF in non-human primates (NHP). This has a unique significance for evaluating a candidate drug for clinical application because the NHP model is the closest to the disease in humans. We are well positioned to provide this quality service for pharmacological studies of CNS candidate drugs.